 The primary objectives are to evaluate the duration of metastatic breast cancer treatments chemotherapy, hormonal therapy and biological therapies according to biological subtype Luminal A, Luminal B, HER2 positive, triple-negative and to evaluate the number of lines of metastatic breast cancer treatments according to biological subtype Luminal A, Luminal B, HER2 positive, triple-negative. 